Sysmex Corporation

Riken Corporation

Daiichi Sankyo Company, Limited

Kirin Beer Kabushiki Kaisha

The Jikei University

Tomokazu Matsuura

Hitoshi Yoshida

Masahiro Sugihara

Takashi Saito

Mikako Shirouzu

Soichi Kojima

Takehisa Matsumoto

Toshitada Takemori

Satoru Mizutani

Katsushi Amano

Masaaki Kawada

Seishi Nagamori

Satoshi Hasumura

Noriko Masubuchi

Tomonori Sugita

Kozo Suto

Masahiro Miura

Takahiro Masaki

Chiemi Tsumagari

Ikuyo Inoue

Disclosed is an isolated monoclonal antibody against a human Transforming Growth Factor-&#x3b2; (TGF-&#x3b2;) Latency Associated Protein (LAP) degradate, the isolated monoclonal antibody being capable of recognizing an integrin binding site in the human TGF-&#x3b2; LAP degradate.

Antibody against human TGF-&#x3b2; LAP degradate, and use thereof

Provided is a test method for discriminating a liver injury type using as an indicator a level of lithocholic acid (hereinafter abbreviated as LCA) in a biological sample of a subject. That is, provided is a test method comprising measuring a level of LCA in a biological sample collected from a subject, and discriminating a liver injury type as hepatocellular injury type, cholestasis type, or a mixed type thereof using the measured level of LCA as an indicator.

Method for investigation of liver damage type

Human hepatoma-derived cell line FLC-4 (deposited with the National Institute of Bioscience and Human-Technology, the Agency of Industrial Science and Technology under Accession Number FERM BP-5165), as well as a method for large-scale production of albumin by culturing the cell line with a radial-flow type bioreactor are provided.

Human hepatoma-derived cell line FLC-4 and method for producing useful

Growing community of inventors

Tokyo, Japan

Tomokazu Matsuura